GlassScriptPhysician profile
Jodie K Labowitz
NPI 1922074012
$4,366.48
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $138 · 2021: $179 · 2022: $1,110 · 2023: $1,081 · 2024: $1,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,290 · Education: $17.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,290.08 |
| Education | $17.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $839.08 | 2019-2024 | |
| Abbvie INC. | $680.39 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $555.11 | 2019-2024 | Entyvio, Eohilia |
| Pfizer INC. | $417.07 | 2019-2024 | |
| Ardelyx, INC. | $234.67 | 2022-2024 | Ibsrela |
| Genzyme Corporation | $234.47 | 2023-2024 | |
| Celgene Corporation | $196.55 | 2021-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $172.73 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $145.12 | 2019-2024 | Simponi Aria, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.24 | 2019-2024 | Xifaxan, Plenvu |
| Nestle Healthcare Nutrition INC. | $107.85 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $90.33 | 2020-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $75.13 | 2022-2024 | Rebyota, Cimzia |
| Ipsen Biopharmaceuticals, INC | $74.68 | 2024 | Iqirvo, Bylvay |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.97 | 2023-2024 | Cyltezo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $49.54 | 2023-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $48.01 | 2022-2024 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $43.00 | 2023-2024 | Voquezna |
| Daiichi Sankyo INC. | $41.76 | 2022 | |
| Celltrion USA INC. | $32.43 | 2024 | Zymfentra, Vegzelma |
| Lilly USA, LLC | $30.63 | 2023 | |
| Fresenius Kabi USA, LLC | $27.44 | 2023 | Idacio |
| Aimmune Therapeutics, INC. | $20.61 | 2024 | |
| Innovation Technologies INC | $19.24 | 2024 | Irrisept |
| Oxford Immunotec USA INC | $15.43 | 2022 | |
| Shionogi INC | $13.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,503.96 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodie Labowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.